CompletedNCT01262170
CigRx Lozenges for Short-Term Smoking Cravings
About this title
Read the official source — NCT01262170Interventional studyAges 23–72United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 23 years to 72 years.
- Listed locations
- MartinsburgSee all locations and recruitment
Study information
Study start dateApril 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 109
- Sponsor
- Rock Creek Pharmaceuticals, Inc.
- Sponsor type
- Other organization
- Study type
- Other
- Intervention type
- Dietary supplement, Other
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 23 Years to 72 Years
- Official registry ID
- NCT01262170
- Official title
Show the full official title
A Randomized, Double-Blind, Active-Controlled, Crossover, Pilot Study to Evaluate the Safety and Efficacy of CigRx™ Lozenge, a Non-Nicotine Non-Tobacco Dietary Supplement, in Daily Smokers in Temporarily Reducing the Desire to Smoke
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Martinsburg
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Rock Creek Pharmaceuticals, Inc.
Who was this study for?
Listed age limits: 23 years to 72 years.
